Deborah K Armstrong

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. Krasner C, Castro C, Penson R, Roche M, Matulonis U, Morgan M, et al. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019;153:223-229 pubmed publisher
    ..5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B. Weekly administered IP carboplatin and IP paclitaxel is tolerable and safe with similar activity with and without concommittant bevacizumab in these 2 trials. ..
  2. Landrum L, Brady W, Armstrong D, Moore K, DiSilvestro P, O Malley D, et al. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016;140:204-9 pubmed publisher
    ..o. b.i.d. in women with recurrent, platinum-sensitive ovarian cancer. With bevacizumab, DLTs were noted in 9 out of 12 patients. Lower doses of veliparib will need to be considered when given in combination with platinum-based therapies. ..
  3. Oliver K, Brady W, Birrer M, Gershenson D, Fleming G, Copeland L, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017;147:243-249 pubmed publisher
    ..Finally, treatment effect was influenced by histology. ..
  4. Moore K, Tritchler D, Kaufman K, Lankes H, Quinn M, Van Le L, et al. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;147:396-401 pubmed publisher
    ..The SNP's identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers. ..